ENTOD Pharmaceuticals Denies Unethical Claims Over PresVu Eye Drops

ENTOD Pharmaceuticals has refuted allegations of unethical and false presentation of its PresVu eye drops. CEO Nikkhil K. Masurkar asserted the disclosures were based on approved indications and clinical data. An official from DCGI contested the company's claims, prompting an official explanation request.

ENTOD Pharmaceuticals has categorically denied allegations of unethical conduct and the false presentation of facts regarding its product, PresVu eye drops. In a late Thursday evening statement, CEO Nikkhil K. Masurkar declared, "We at ENTOD Pharmaceuticals hereby declare that we have not made any unethical or false presentation of facts to the media or public when it comes to PresVu eye drops. All facts disclosed to the media are strictly based on the approved indication for the treatment of presbyopia in adults and the Phase 3 clinical trial data generated by us."

The company further distanced itself from certain opinions and claims printed in news stories, asserting that these do not represent ENTOD Pharmaceuticals or any of its spokespeople. The unprecedented media interest in the therapy has, according to the company, led to sensationalization. However, a top official source from the Drug Controller General of India (DCGI) told ANI that the company's claims are both unethical and falsely presented, prompting an official explanation request from the company.

ENTOD Pharmaceuticals had earlier claimed that PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for those with presbyopia, a common age-related vision condition affecting individuals over 40. The company also stated that PresVu has been applied for a patent regarding its formulation and process. Moreover, CEO Masurkar emphasized during the product's launch that PresVu represents years of dedicated research and development, and the DCGI approval marks a significant milestone in their mission to transform eye care in India.

(With inputs from agencies.)